Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesME Therapeutics Holdings Inc.

ME Therapeutics Holdings Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.05 CAD -0.05 ( 4.55%)
Last update at 2026-11-04T19:52:00Z
VOLUME
10428
Market Cap
75.12M

Momentum Score

…

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.05
Low
1.10
High
52 Week Price Range
2.00
Low
10.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Publicly available information on METX.CN is sparse and the company's core business and financials are not well documented in common regulatory filings or investor materials. Because disclosures are minimal, potential long-term growth drivers and competitive position cannot be reliably identified; investors should consult the issuer's latest filings and direct communications for clarity.

The main investment risk is low transparency combined with likely low trading liquidity, which increases financing and execution uncertainty and makes assessment of business prospects difficult.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.10
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-93.72%
Net Debt
-
ROCE
-80.47%
Diluted EPS TTM
-0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Type yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Income before tax -1.19M -1.29M -6.52M -0.15M
Net income -1.19M -1.29M -6.52M -0.15M
Selling general administrative 0.78M 1.06M 0.95M 0.10M
Reconciled depreciation 0.08M - - -
Operating income -1.22M -1.37M -6.55M -0.16M
Interest expense 0.01M 0.00M 0.01M 0.01M
Interest income 0.04M 0.03M 0.01M -
Net interest income 0.03M - - -
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 1.22M - - -
Net income from continuing ops -1.19M - - -
Net income applicable to common shares - -1.29M -6.52M -0.15M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Type yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total assets 1.76M 1.54M 0.67M 0.10M
Intangible assets - 0.00M 0.00M 0.00M
Total liab 0.26M 0.06M 0.15M 0.23M
Total stockholder equity 1.50M 1.48M 0.52M -0.13M
Common stock - 6.11M 4.56M 0.51M
Capital stock 8.59M - - -
Retained earnings -9.73M -4.64M -4.03M -0.66M
Cash 1.35M 1.50M 0.65M 0.08M
Total current liabilities 0.25M 0.06M 0.15M 0.17M
Short term debt - 0.00M 0.00M 0.13M
Other stockholder equity - - 0.00M 0.02M
Property plant equipment - 0.00M 0.00M 0.00M
Total current assets 1.50M 1.54M 0.67M 0.10M
Short term investments 0.06M - - -
Long term debt - - 0.00M 0.06M
Accounts payable 0.16M - - -
Non current assets total 0.26M - - -
Capital lease obligations 0.07M - - -
Long term debt total - 0.00M 0.00M 0.06M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Type yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Investments -0.06M - - -
Total cashflows from investing activities - 0.00M 0.76M -
Net borrowings -0.05M - - -
Total cash from financing activities 1.00M 1.51M 0.12M 0.14M
Net income -1.19M -1.29M -6.52M -0.15M
Change in cash -0.15M 0.85M 0.57M 0.00M
Begin period cash flow 1.50M - - -
End period cash flow 1.35M - - -
Total cash from operating activities -0.86M -0.66M -0.30M -0.14M
Issuance of capital stock 0.00M - - -
Depreciation 0.08M 0.00M 0.00M 0.00M
Other cashflows from investing activities - 0.00M 0.76M -
Sale purchase of stock - 1.55M - 0.00M
Other cashflows from financing activities - -0.01M - -
Capital expenditures 0.22M 0.00M 0.00M 0.00M
Change in working capital 0.06M -0.06M 0.04M -0.01M
Stock based compensation 0.17M - - -
Other non cash items 0.01M - - -
Free cash flow -1.08M - - -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
METX
ME Therapeutics Holdings Inc.		 -0.05
4.55%		 1.05 - - - 72.00
DRUG
Bright Minds Biosciences Inc		 -10.97
29.58%		 26.11 - - - 13.50
TELI
Telescope Innovations Corp.		 0.01
1.56%		 0.33 - - 4.32 6.45
DTC
Defence Therapeutics Inc		 -0.01
1.47%		 0.34 - - - 89.80
LOBE
Lobe Sciences Ltd		 -
-%		 0.04 - - 2.44 15.58

Profile*

ME Therapeutics Holdings Inc.

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.

177 Robson Street, Vancouver, BC, Canada, V6B 0N3

236 516 7714

https://www.metherapeutics.com

Name Title Year Born
Dr. Salim Zulifkar Dhanji Ph.D. CEO & Director NA
Mr. Jamil Kassam Corporate Secretary NA
Mr. Karim F. Lalji M.S., SM Chief Business Officer NA
Dr. Salim Zulifkar Dhanji Ph.D. Founder, CEO & Director NA
Mr. Quinn Martin C.A., CPA Chief Financial Officer 1983

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…